Pradaxa Lawsuit News: European Regulators Recommend Approval of Expanded Indications for Pradaxa, Bernstein Liebhard LLP Reports

Share Article

The Firm is investigating Pradaxa lawsuits on behalf patients who allegedly suffered uncontrollable internal bleeding due to their use of the blood thinner.

Free Case Review
The European recommendation comes at a time when thousands of plaintiffs are filing Pradaxa lawsuits in the U.S. that claim the drug caused uncontrollable internal bleeding.

As Pradaxa lawsuits ( ) mount in the U.S., Bernstein Liebhard LLP notes that the European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended that the blood thinner’s approved uses be expanded to include treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as prevention of recurrent DVT and PE in adults. According to a report published by on April 29th, Boehringer Ingelheim maintains that DVT or PE patients taking Pradaxa experienced significantly lower rates of bleeding than those taking warfarin, a blood thinner that has been in use for decades.*

“The European recommendation comes at a time when thousands of plaintiffs are filing Pradaxa lawsuits in the U.S. that claim the drug caused uncontrollable internal bleeding. Pradaxa patients should be informed of its potential side effects, especially the fact that there exists no readily-available antidote for Pradaxa bleeding complications,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is offering free and confidential case evaluations to individuals who allegedly experienced cerebral hemorrhage, gastrointestinal bleeding, or other episodes of serious internal bleeding due to Pradaxa.

Pradaxa Bleeding Litigation
Pradaxa was launched on the U.S. market in 2010, and was initially approved to decrease the risk of strokes in people who suffer from atrial fibrillation. According to court documents, more than 2,500 lawsuits have been filed in the U.S. District Court, Southern District of Illinois on behalf of alleged victims of Pradaxa bleeding side effects. Among other things, these lawsuits claim that Boehringer Ingelheim wrongly touted Pradaxa as an improvement to warfarin, and point out that there currently exists no readily-available method for reversing serious internal bleeding that sometimes occurs with Pradaxa. Warfarin bleeding, by contrast, can be stopped via the administration of vitamin K. (In Re: Pradaxa (Dabigatran Etexilate) Products Liability Litigation – MDL No. 2385)

In February, a report aired by 7 Action News in Detroit asserted that Pradaxa may be the most complained about drug in the U.S. According to the broadcast, the FDA has received reports of 12,494 injuries and 1,158 deaths among Pradaxa users since the blood thinner was launched in the U.S. Many of these cases detailed episodes of uncontrollable internal bleeding. **

Individuals who allegedly suffered serious Pradaxa bleeding side effects may be entitled to compensation from Boehringer Ingelheim. Find out more about Pradaxa lawsuits at Bernstein Liebhard LLP’s website. Please call 800-511-5092 to schedule a free, no obligation case review.

* ,, April 29, 2014
**, 7 Action News, February 25, 2014

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorneys fees unless their case results in a successful recovery on their behalf. New York State’s contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery. As a result, the Firm’s fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a plaintiff’s recovery.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at)consumerinjurylawyers(dot)com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Felecia L. Stern
Visit website